A journey of celecoxib from pain to cancer

• Published in: Prostaglandins & other lipid mediators 2020-04, Vol.147, p.106379-106379, Article 106379
• Main Authors: Saxena, Pratiksha, Sharma, Pramod K., Purohit, Priyank
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Antineoplastic action; Cardiovascular Diseases - prevention & control; Cardiovascular risk; Celecoxib - therapeutic use; Celecoxib disposition; Formulation approaches; Humans; Inflammation - prevention & control; Neoplasms - drug therapy; Pain - prevention & control; Pain signaling
• ISSN: 1098-8823
• DOI: 10.1016/j.prostaglandins.2019.106379

[Display omitted] •Pain is an alarm for the body, signaling infection and injury.•COX-2 inhibitor drives its therapeutic potential from pain to uncontrolled cell growth.•Special emphasis on cardiovascular risk related to dose and dosing interval of therapeutic agent.•The promising formulation approaches to overcome the issues of drug that belongs to BCS class II. The most enthralling and versatile class of drugs called the Non-steroidal anti-inflammatory (NSAIDs) showed its therapeutic utility in inflammation, beginning from the era of classic drug ‘Aspirin’. NSAIDs and their well-established action based on inhibiting the COX-1 and COX-2 enzyme leads to blockage of prostaglandin pathway. They further categorized into first generation (non-selective inhibitor) and second generation (selective COX-2 inhibitors). Selective COX-2 inhibitors has advantage over non-selective in terms of their improved safety profile of gastro-intestinal tract. Rejuvenating and recent avenues for COXIBS (selective COX-2 inhibitors) explains its integrated role in identification of biochemical pain signaling as well as its pivotal key role in cancer chemotherapy. A key role player in this class is the Celecoxib (only FDA approved COXIB) a member of Biopharmaceutical classification system (BCS) II. Low solubility and bioavailability issues related with celecoxib lead to the development and advancement in the discovery and research of some possible formulation administered either orally, topically or via transdermal route. This review article intent to draw the bead on Celecoxib and it clearly explain extensive knowledge of its disposition profile, its dynamic role in cancer at cellular level and cardiovascular risk assessment. Some of the possible formulations approaches with celecoxib and its improvement aspects are also briefly discussed.